-
Company Insights
Innovation and Patenting activity of Ildong Pharmaceutical Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Ildong Pharmaceutical Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Irinotecan Hydrochloride in Metastatic Adenocarcinoma of The Pancreas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Irinotecan Hydrochloride in Metastatic Adenocarcinoma of The Pancreas Drug Details: Irinotecan Hydrochloride is a semisynthetic...
-
Product Insights
NewCachexia – Drugs In Development, 2024
Empower your strategies with our Cachexia – Drugs In Development, 2024 report and make more profitable business decisions. Cachexia, also known as wasting syndrome, is characterized by loss of skeletal muscle mass. Symptoms include involuntary unintentional weight loss, skeletal muscle wasting, and anorexia. Risk factors include HIV, cancer, chronic obstructive pulmonary disease, congestive heart failure, rheumatoid arthritis, and cystic fibrosis. Treatment includes appetite stimulants, exercise, and dietary supplements. The Cachexia drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewMuscle Wasting Disorders – Drugs In Development, 2024
Empower your strategies with our Muscle Wasting Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Muscle wasting is evident in diverse pathologies like cancer, chronic kidney disease, heart failure, chronic obstructive pulmonary disease (COPD), and during aging or extended inactivity. Diminished muscle mass and function correlate with increased morbidity and mortality, along with a diminished quality of life. Elevated levels of pro-inflammatory cytokines are frequently observed in the plasma of individuals experiencing muscle wasting conditions, prompting...
-
Product Insights
NewNeuromuscular Disorders – Drugs In Development, 2024
Empower your strategies with our Neuromuscular Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Neuromuscular disorders are conditions that affect the function of the nerves and muscles in the body. They can cause muscle weakness, fatigue, pain, spasms, and other symptoms. Neuromuscular disorders can be inherited or acquired, and they can affect different parts of the neuromuscular system, such as the peripheral nerves, the skeletal muscles, or the neuromuscular junction. Some examples of neuromuscular disorders are...
-
Product Insights
NewReflux Esophagitis (Gastroesophageal Reflux Disease) – Drugs In Development, 2024
Empower your strategies with our Reflux Esophagitis (Gastroesophageal Reflux Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Gastroesophageal reflux disease (GERD) refers to a condition where the liquid content of the stomach refluxes into the esophagus. It is a chronic condition. The symptoms of GERD are nausea, heartburn, and vomiting. The predisposing factors include eating large meals, which can cause the lower esophageal sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food, and...
-
Product Insights
NewAcute Lung Injury – Drugs In Development, 2024
Empower your strategies with our Acute Lung Injury – Drugs In Development, 2024 report and make more profitable business decisions. Acute lung injury (ALI) is a severe and potentially life-threatening condition characterized by sudden and significant damage to the lungs, resulting in impaired gas exchange and respiratory function. ALI is now often grouped under the broader term acute respiratory distress syndrome (ARDS). ALI can result from various direct causes, including pneumonia, aspiration of gastric contents, near-drowning, inhalation of toxins or smoke,...
-
Product Insights
NewEsophageal Diseases – Drugs In Development, 2024
Empower your strategies with our Esophageal Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Esophageal Diseases, which are characterized by weakened muscles and narrowing of the esophageal opening, often lead to difficulties in digestion and swallowing. The esophagus is the tube-shaped muscle that connects the throat to the stomach. Esophageal diseases occur when the esophagus muscle and opening become weak. The most common problem with the esophagus is GERD (gastroesophageal reflux disease). With GERD, a muscle...
-
Product Insights
NewEsophagitis – Drugs In Development, 2024
Empower your strategies with our Esophagitis – Drugs In Development, 2024 report and make more profitable business decisions. Esophagitis is inflammation of the esophagus, often triggered by acid reflux, infections, medications, or allergies. Symptoms include painful swallowing, heartburn, chest pain, and sometimes bleeding. Common types include reflux esophagitis (due to GERD) and infectious esophagitis (caused by viruses, fungi, or bacteria). Diagnosis involves endoscopy and sometimes imaging tests. Treatment focuses on addressing the underlying cause, using acid-suppressing medications, antibiotics, antifungals, or lifestyle...
-
Product Insights
NewLiver Cirrhosis – Drugs In Development, 2024
Empower your strategies with our Liver Cirrhosis – Drugs In Development, 2024 report and make more profitable business decisions. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver, which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness, and nausea. Treatment includes liver transplant surgery. The...